Sunday, January 25, 2015 Last update: Yesterday, 10:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Enzo Biochem Announces August 18, 2014 as Date of Markman Hearing in Patent Infringement Lawsuit Against Leading Life Sciences Companies

Companies mentioned in this article: Enzo Biochem, Inc.

NEW YORK -- (BUSINESS WIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that U.S. District Judge Leonard P. Stark has established August 18th as the date for a patent claim construction hearing, also called a Markman hearing, involving Enzo Life Science’s U.S. Patents Nos. 6,992,180, 7,064,197, and 8,097,405. The hearing will be held in Delaware District Court. One or more of these patents is asserted against Abbott Labs, Affymetrix, Agilent, Becton Dickinson, Gen-Probe, Hologic, Illumina, Life Technologies, Luminex, Roche, and Siemens, and their related entities.

At such a hearing, the Judge will be asked to issue rulings regarding the language and interpretation of Enzo's patents at issue in the case. Markman hearings are considered a key event in a patent lawsuit. The upcoming Markman ruling will define the property rights for the technologies that Enzo has invented. Such rulings often drive and inform many aspects of the litigation.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2013. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.


Copyright © Business Wire 2015
Contact:

For Enzo Biochem, Inc.
Anreder & Company
Steven Anreder, 212-532-3232
steven.anreder@anreder.com
or
CEOcast, Inc.
Michael Wachs, 212-732-4300
mwachs@ceocast.com